Third, long-term safety data remain limited, particularly for chronic glucagon receptor activation
Lancet 375:22232233 Fadini GP, Avogaro A (2017) SGTL2 inhibitors and amputations in the US FDA adverse event reporting system
But that could be, you know, from my perspective, you know, something that is addressed through, you know, requiring participation in a lifestyle modification program, because that is, you know, how these drugs were approved to be used versus a particular, set of providers
All patients switching from semaglutide must start tirzepatide at 2.5mg weekly regardless of their previous dose, even if they were on maximum 2.4mg semaglutide, due to tirzepatide's dual GLP-1/GIP receptor mechanism
Van Dril told Drugwatch